

ASX ANNOUNCEMENT

14 November 2025

Appendix 3Y correction




Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") wishes to advise a correction to the Appendix 3Y released on 1 September 2025.

The Appendix 3Y lodged on 1 September 2025 for Fleta Jennifer Solomon incorrectly noted that 2 million unlisted options, exercisable at \$0.1725 each and expiring on 31 July 2028, were acquired. The correct number of options was 1.2 million. All other disclosures on the Appendix 3Y were correct.

A revised Appendix 3Y is attached.

ENDS

BY ORDER OF THE COMPANY SECRETARY

A stylized, handwritten signature in black ink, appearing to be "Alistair Warren".

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Paul Long
Managing Director

Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: <https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>

Access past Cannabis Wraps here: <https://www.investlittlegreenpharma.com/site/investor-centre/cannabis-industry-wrap>



Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Fleta Jennifer Solomon
Date of last notice	6 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund Ms Solomon is a director of the trustee and beneficiary
Date of change	1 September 2025
No. of securities held prior to change * opening balance from previous interest notice reduced by 36,000 for conversion of share rights on 24 April 2023	<u>Direct</u> 20,723,216 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 1,000,000 Retention Rights 1,200,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027 <u>Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund</u> 1,150,000 fully paid ordinary shares
Class	Unlisted Options, exercisable at \$0.1725 each, expiring 31 July 2028

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	1,200,000 Unlisted Options, exercisable at \$0.1725 each, expiring 31 July 2028
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil. Options under the Company's Long Term Incentive Plan as approved by shareholders on 21 Aug 2025
No. of securities held after change	<p><u>Direct</u></p> <p>20,723,216 fully paid ordinary shares</p> <p>500,000 Class F Performance Rights</p> <p>500,000 Class G Performance Rights</p> <p>500,000 Class H Performance Rights</p> <p>500,000 Class I Performance Rights</p> <p>500,000 Class J Performance Rights</p> <p>500,000 Class K Performance Rights</p> <p>1,000,000 Retention Rights</p> <p>1,200,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027</p> <p>1,200,000 Unlisted Options, exercisable at \$0.1725 each, expiring 31 July 2028</p> <p><u>Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund</u></p> <p>1,150,000 fully paid ordinary shares</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Options under the Company's Long Term Incentive Plan as approved by shareholders on 21 Aug 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.